Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.64 |
| ▸ | CA9 | Q16790 | 6/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | IL2 | P60568 | 2/20 | 0.48 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.48 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | CASP7 | P55210 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8098515 | 0.91 | CA12 (0.62) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL724524 | 0.91 | CA12 (0.61) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL724528 | 0.91 | CA12 (0.61) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL3366849 | 0.87 | CA12 (0.71) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL3361018 | 0.86 | CA12 (0.70) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL382083 | 0.83 | CA12 (0.74) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL6228083 | 0.83 | CA12 (0.74) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL18137941 | 0.79 | CA12 (0.55) | CA12CA9CA1CA2SMN1; SMN2 | |
| SCHEMBL1526661 | 0.78 | CA12 (1.00) | CA12CA9CA1CA2NPC1 | |
| SCHEMBL755988 | 0.78 | CA12 (1.00) | CA12CA9CA1CA2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244813-B1 | AMPLIFICATION BASED POLYMORPHISM DETECTION | ABBOTT LAB (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110171648-A1 | METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS | ABBOTT LABORATORIES (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2311993-A2 | Method of detecting and quantifying hepatitis C virus | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2163651-A1 | Method of detecting and quantifying hepatitis C virus | Abbott Laboratories (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1540011-B1 | METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS | ABBOTT LAB (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7250252-B2 | Monitor preferential nucleotide sequences in sample; obtain nucleotide sequences, incubate with amplificaion mixture, incubate with priers, recover nucleotide sequences, detect target sequences | ABBOTT LABORATORIES | 2007-07-31 | — | — | US | disclosed |
| US-7211381-B1 | β2 andrenergic polymorphism detection | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20050202417-A1 | Method of detecting and quantifying hepatitis C virus | ABBOTT LABORATORIES | 2005-09-15 | — | — | US | disclosed |
| EP-1540011-A2 | METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1440081-A4 | BETA 2 ADRENERGIC POLYMORPHISM DETECTION | ABBOTT LAB (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004011612-A2 | METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS | ABBOTT LABORATORIES (US) | 2004-02-05 | — | — | WO | disclosed |
| US-6593092-B2 | Amplification; detection | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2003031641-A2 | BETA 2 ADRENERGIC POLYMORPHISM DETECTION | ABBOTT LABORATORIES (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1244813-A2 | AMPLIFICATION BASED POLYMORPHISM DETECTION | ABBOTT LABORATORIES (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137069-A1 | Beta 2 adrenergic polymorphism detection | ABBOTT LABORATORIES | 2002-09-26 | — | — | US | disclosed |
| US-20020102549-A1 | Amplification based polymorphism detection | ABBOTT LABORATORIES | 2002-08-01 | — | — | US | disclosed |
| WO-2001049883-A2 | AMPLIFICATION BASED POLYMORPHISM DETECTION | ABBOTT LABORATORIES (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-1062361-A2 | WATER-SOLUBLE COUMARIN FLUORESCENT ENZYME SUBSTRATES | ABBOTT LABORATORIES (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5998593-A | COUMARIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999046402-A2 | WATER-SOLUBLE COUMARIN FLUORESCENT ENZYME SUBSTRATES | ABBOTT LABORATORIES (US) | 1999-09-16 | — | — | WO | disclosed |